These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 9003579)

  • 1. Alternatives to structural modeling.
    Veng-Pedersen P
    Methods Find Exp Clin Pharmacol; 1996; 18 Suppl C():49-50. PubMed ID: 9003579
    [No Abstract]   [Full Text] [Related]  

  • 2. Structural modeling: simultaneous pharmacokinetic-pharmacodynamic modeling.
    Gambús PL
    Methods Find Exp Clin Pharmacol; 1996; 18 Suppl C():47-8. PubMed ID: 9003578
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of erythropoietin following single-dose subcutaneous administration in preterm infants.
    Krishnan R; Shankaran S; Krishnan M; Kauffman RE; Kumar P; Lucena J
    Biol Neonate; 1996; 70(3):135-40. PubMed ID: 8894079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Connection of pharmacokinetics and pharmacodynamics--how does it work?
    Cawello W
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):414-7. PubMed ID: 9352389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations.
    Kampf D; Eckardt KU; Fischer HC; Schmalisch C; Ehmer B; Schostak M
    Nephron; 1992; 61(4):393-8. PubMed ID: 1501734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress and outlook in the development of pharmacology].
    Kharkevich DA
    Farmakol Toksikol; 1989; 52(6):106-20. PubMed ID: 2483140
    [No Abstract]   [Full Text] [Related]  

  • 7. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin.
    Xenocostas A; Cheung WK; Farrell F; Zakszewski C; Kelley M; Lutynski A; Crump M; Lipton JH; Kiss TL; Lau CY; Messner HA
    Eur J Clin Pharmacol; 2005 May; 61(3):189-95. PubMed ID: 15776276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics/pharmacodynamics of recombinant human erythropoietins in doping control.
    Varlet-Marie E; Gaudard A; Audran M; Bressolle F
    Sports Med; 2003; 33(4):301-15. PubMed ID: 12688828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report.
    Heatherington AC; Schuller J; Mercer AJ
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):11-6. PubMed ID: 11308269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Summary of achievements in drug therapy in the 20th century].
    Danysz A
    Pol Tyg Lek; 1988 Dec 19-26; 43(51-52):1643-6. PubMed ID: 3077454
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics and haematological parameters of recombinant human erythropoietin after subcutaneous administrations in horses.
    Souillard A; Audran M; Bressolle F; Jaussaud P; Gareau R
    Biopharm Drug Dispos; 1996 Dec; 17(9):805-15. PubMed ID: 8968532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin.
    Veng-Pedersen P; Freise KJ; Schmidt RL; Widness JA
    J Pharm Pharmacol; 2008 Oct; 60(10):1321-34. PubMed ID: 18812025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Grounds for the integration of pharmacokinetic-pharmacodynamic data.
    Barbanoj MJ; Salazar G; Morte A; Antonijoan RM; Gich I; Jané F
    Methods Find Exp Clin Pharmacol; 1996; 18 Suppl C():43-5. PubMed ID: 9003577
    [No Abstract]   [Full Text] [Related]  

  • 14. Whither pharmacometrics?: present state and future choices.
    Vicini P; Smith BP
    Clin Pharmacol Ther; 2014 Jun; 95(6):567-71. PubMed ID: 24842634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in rats.
    Kato M; Okano K; Sakamoto Y; Miura K; Uchimura T; Saito K
    Arzneimittelforschung; 2001 Jan; 51(1):91-5. PubMed ID: 11215332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of erythropoietin in intact and anephric dogs.
    Fu JS; Lertora JJ; Brookins J; Rice JC; Fisher JW
    J Lab Clin Med; 1988 Jun; 111(6):669-76. PubMed ID: 3373111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and distribution of recombinant human erythropoietin in rats with renal dysfunction.
    Kinoshita H; Ohishi N; Tokura S; Okazaki A
    Arzneimittelforschung; 1992 May; 42(5):682-6. PubMed ID: 1530684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand-based approaches to in silico pharmacology.
    Vidal D; Garcia-Serna R; Mestres J
    Methods Mol Biol; 2011; 672():489-502. PubMed ID: 20838981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of epoetin (recombinant human erythropoietin) after long term therapy in patients undergoing haemodialysis and haemofiltration.
    Gladziwa U; Klotz U; Bäumer K; Zollinger R; Mann H; Sieberth HG
    Clin Pharmacokinet; 1993 Aug; 25(2):145-53. PubMed ID: 8403738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of pharmacology in the 20th century: a 19th century prediction.
    Burks TF
    Proc West Pharmacol Soc; 1999; 42():161-3. PubMed ID: 10697715
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.